Filing Flows › Comparisons › BGLC vs ACON
BioNexus Gene Lab vs Aclarion: BGLC and ACON compared
BioNexus Gene Lab is the larger company: $76K of revenue in its latest quarter (Q2 2026) against $34K for Aclarion (Q3 2026). Aclarion is growing faster (+78% against -97% a year earlier).
Where the money goes: BGLC and ACON
BioNexus Gene Lab (BGLC) · Q2 2026
BioNexus Gene Lab, Q2 2026: revenue $76K (-97% year over year), operating margin -370.8%, net loss $286K, operating cash flow −$422K. The chart follows the revenue to costs, profit and cash.
Aclarion (ACON) · Q3 2026
Aclarion, Q3 2026: revenue $34K (+78% year over year), net loss $2.6M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| BioNexus Gene Lab (BGLC) | Aclarion (ACON) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $76K | $34K |
| Revenue growth, Y/Y | -97% | +78% |
| Operating margin | -370.8% | n/m |
| Net earnings | −$286K | −$2.6M |
| Net margin | -376.1% | — |
| Operating cash flow | −$422K | −$2.0M |
Questions
Which is bigger, BioNexus Gene Lab or Aclarion?
BioNexus Gene Lab is the larger company: $76K of revenue in its latest quarter (Q2 2026) against $34K for Aclarion (Q3 2026).
Is BioNexus Gene Lab or Aclarion growing faster?
Aclarion is growing faster (+78% against -97% a year earlier).
More: BioNexus Gene Lab earnings · how BioNexus Gene Lab makes money · Aclarion earnings · how Aclarion makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.